Skip to main content
. Author manuscript; available in PMC: 2016 Mar 24.
Published in final edited form as: Biomaterials. 2010 May 15;31(23):6031–6038. doi: 10.1016/j.biomaterials.2010.04.009

Fig. 2.

Fig. 2

Pharmacokinetic study (plasmatic rivastigmine concentration CRiv vs. time) of the following formulations: PK-Oil-300-5 (■), PK-BTM-300-15 (●) and PK-SAM-300-15 (◆) (Mean ± SEM, n = 8). Inset represents the early time points.